Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Celcuity (CELC)
NASDAQ:CELC
Holding CELC?
Track your performance easily
CELC Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$10.43 - $22.19
Previous Close$15.7
Volume185.36K
Average Volume (3M)282.75K
Market Cap
$565.08M
Enterprise Value$394.82M
Total Cash (Recent Filing)$283.07M
Total Debt (Recent Filing)$96.51M
Price to Earnings (P/E)―
Beta0.35
Next Earnings
Nov 14, 2024EPS Estimate
-$0.65Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.74
Shares Outstanding37,028,733
10 Day Avg. Volume226,920
30 Day Avg. Volume282,755
Standard Deviation0.25
R-Squared0.02
Alpha0.02
Financial Highlights & Ratios
Price to Book (P/B)3.29
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-8.10
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-12.84
Forecast
1Y Price Target
$29.75Price Target Upside94.95% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
Celcuity News
Bulls Say, Bears Say
Bulls Say
Clinical TrialsCelcuity is focused on developing their pan-PI3K and mTOR inhibitor, called gedatolisib, for advanced ER+ breast cancer, as well as metastatic castration-resistant prostate cancer (mCRPC).
Financial HealthCelcuity ended 2Q:24 with $283M including ~$129M from recent financings, extending cash runway through 2026.
Market PotentialAnalyst's recommendation maintains a Buy Rating and $23 Target.
Bears Say
Clinical DevelopmentThe recent announcement of a slight delay in the WT readout has caused concerns among some investors that the control arm may be overperforming relative to expectations.
Financial PerformanceThe company reported no revenues, and a net loss of $0.62 per diluted share, compared to consensus estimate of no revenues and a net loss of $0.68 per diluted share.
Share VolatilityPFS in the range of 7-8.5 months could create volatility for CELC shares, especially at the lower range, where some investors may question the clinical benefits versus oral agents.
---
Ownership Overview
30.42% Insiders
11.68% Mutual Funds
0.58% Other Institutional Investors
47.76% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
CELC FAQ
What was Celcuity’s price range in the past 12 months?
Celcuity lowest stock price was $10.43 and its highest was $22.19 in the past 12 months.
What is Celcuity’s market cap?
Currently, no data Available
When is Celcuity’s upcoming earnings report date?
Celcuity’s upcoming earnings report date is Nov 14, 2024 which is in 2 days.
How were Celcuity’s earnings last quarter?
Celcuity released its earnings results on Aug 14, 2024. The company reported -$0.62 earnings per share for the quarter, beating the consensus estimate of -$0.679 by $0.059.
Is Celcuity overvalued?
According to Wall Street analysts Celcuity’s price is currently Undervalued.
Does Celcuity pay dividends?
Celcuity does not currently pay dividends.
What is Celcuity’s EPS estimate?
Celcuity’s EPS estimate is -$0.65.
How many shares outstanding does Celcuity have?
Celcuity has 37,030,155 shares outstanding.
What happened to Celcuity’s price movement after its last earnings report?
Celcuity reported an EPS of -$0.62 in its last earnings report, beating expectations of -$0.679. Following the earnings report the stock price went down -3.429%.
Which hedge fund is a major shareholder of Celcuity?
Among the largest hedge funds holding Celcuity’s share is Perceptive Advisors LLC. It holds Celcuity’s shares valued at 39M.
---
Celcuity Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$29.75 (94.95% Upside)
$29.75 (94.95% Upside)
Blogger Sentiment
Bullish
CELC Sentiment 100%
Sector Average 73%
Sector Average 73%
Hedge Fund Trend
Increased
By 401.0K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days ▲ 2.5%
Last 30 Days ▲ 0.8%
Last 30 Days ▲ 0.8%
Technicals
SMA
Negative
20 days / 200 days
Momentum
45.77%
12-Months-Change
Fundamentals
Return on Equity
-57.59%
Trailing 12-Months
Asset Growth
90.56%
Trailing 12-Months
Company Description
Celcuity
Celcuity, Inc. is cellular analysis company. The company discovers new cancer sub-types and commercializing diagnostic tests designed to improve the clinical outcomes of cancer patients treated with targeted therapies. Its proprietary CELx diagnostic platform is the commercially ready technology that uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the targeted therapy that treats it. The company was founded in January 2012 by Brian Sullivan and Lance Laing and is headquartered in Minneapolis, MN.
---
CELC Earnings Call
Q2 2024
0:00 / 0:00
---
CELC Stock 12 Month Forecast
Average Price Target
$29.75
▲(94.95% Upside)
Technical Analysis
Ocular Therapeutix
―
Kala Pharmaceuticals
―
EyePoint Pharmaceuticals
―
Karyopharm Therapeutics
―
Best Analysts Covering CELC
1 Year
---